Cargando…

Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab

The immune checkpoint inhibitors opened a new era for the treatment of melanoma. Nowadays, combined immune checkpoint inhibitors are administered to provide additive or synergistic effects on anti-melanoma immunity. The use of these drugs comes with serious adverse events related to excessive immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Seyed Jafari, S. Morteza, Feldmeyer, Laurence, Hunger, Robert E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577175/
https://www.ncbi.nlm.nih.gov/pubmed/33117707
http://dx.doi.org/10.3389/fonc.2020.573527
_version_ 1783598149297766400
author Seyed Jafari, S. Morteza
Feldmeyer, Laurence
Hunger, Robert E.
author_facet Seyed Jafari, S. Morteza
Feldmeyer, Laurence
Hunger, Robert E.
author_sort Seyed Jafari, S. Morteza
collection PubMed
description The immune checkpoint inhibitors opened a new era for the treatment of melanoma. Nowadays, combined immune checkpoint inhibitors are administered to provide additive or synergistic effects on anti-melanoma immunity. The use of these drugs comes with serious adverse events related to excessive immune activation. Here, we present development of extragenital lichen sclerosus in a patient with metastatic malignant melanoma, during the combined therapy with checkpoint inhibitors.
format Online
Article
Text
id pubmed-7577175
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-75771752020-10-27 Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab Seyed Jafari, S. Morteza Feldmeyer, Laurence Hunger, Robert E. Front Oncol Oncology The immune checkpoint inhibitors opened a new era for the treatment of melanoma. Nowadays, combined immune checkpoint inhibitors are administered to provide additive or synergistic effects on anti-melanoma immunity. The use of these drugs comes with serious adverse events related to excessive immune activation. Here, we present development of extragenital lichen sclerosus in a patient with metastatic malignant melanoma, during the combined therapy with checkpoint inhibitors. Frontiers Media S.A. 2020-10-07 /pmc/articles/PMC7577175/ /pubmed/33117707 http://dx.doi.org/10.3389/fonc.2020.573527 Text en Copyright © 2020 Seyed Jafari, Feldmeyer and Hunger. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Seyed Jafari, S. Morteza
Feldmeyer, Laurence
Hunger, Robert E.
Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab
title Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab
title_full Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab
title_fullStr Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab
title_full_unstemmed Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab
title_short Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab
title_sort development of extragenital lichen sclerosus in malignant melanoma patients treated with ipilimumab in combination with nivolumab
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577175/
https://www.ncbi.nlm.nih.gov/pubmed/33117707
http://dx.doi.org/10.3389/fonc.2020.573527
work_keys_str_mv AT seyedjafarismorteza developmentofextragenitallichensclerosusinmalignantmelanomapatientstreatedwithipilimumabincombinationwithnivolumab
AT feldmeyerlaurence developmentofextragenitallichensclerosusinmalignantmelanomapatientstreatedwithipilimumabincombinationwithnivolumab
AT hungerroberte developmentofextragenitallichensclerosusinmalignantmelanomapatientstreatedwithipilimumabincombinationwithnivolumab